Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes

Yona Goldshmit, Rosalia Matteo, Tamar E Sztal, Felix Ellett, Frisca Frisca, Kelli Moreno, Duncan Crombie, Graham J Lieschke, Peter D Currie, Roger A Sabbadini, Alice Pebay

Research output: Contribution to journalArticleResearchpeer-review

40 Citations (Scopus)

Abstract

Evidence suggests a proinflammatory role of lysophosphatidic acid (LPA) in various pathologic abnormalities, including in the central nervous system. Herein, we describe LPA as an important mediator of inflammation after spinal cord injury (SCI) in zebrafish and mice. Furthermore, we describe a novel monoclonal blocking antibody raised against LPA that potently inhibits LPA s effect in vitro and in vivo. This antibody, B3, specifically binds LPA, prevents it from interacting with its complement of receptors, and blocks LPA s effects on the neuronal differentiation of human neural stem/progenitor cells, demonstrating its specificity toward LPA signaling. When administered systemically to mice subjected to SCI, B3 substantially reduced glial inflammation and neuronal death. B3-treated animals demonstrated significantly more neuronal survival upstream of the lesion site, with some functional improvement. This study describes the use of anti-LPA monoclonal antibody as a novel therapeutic approach for the treatment of SCI.
Original languageEnglish
Pages (from-to)978 - 992
Number of pages15
JournalAmerican Journal of Pathology
Volume181
Issue number3
DOIs
Publication statusPublished - 2012

Cite this

Goldshmit, Yona ; Matteo, Rosalia ; Sztal, Tamar E ; Ellett, Felix ; Frisca, Frisca ; Moreno, Kelli ; Crombie, Duncan ; Lieschke, Graham J ; Currie, Peter D ; Sabbadini, Roger A ; Pebay, Alice. / Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes. In: American Journal of Pathology. 2012 ; Vol. 181, No. 3. pp. 978 - 992.
@article{924679875ef8497c837908b2aec236f8,
title = "Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes",
abstract = "Evidence suggests a proinflammatory role of lysophosphatidic acid (LPA) in various pathologic abnormalities, including in the central nervous system. Herein, we describe LPA as an important mediator of inflammation after spinal cord injury (SCI) in zebrafish and mice. Furthermore, we describe a novel monoclonal blocking antibody raised against LPA that potently inhibits LPA s effect in vitro and in vivo. This antibody, B3, specifically binds LPA, prevents it from interacting with its complement of receptors, and blocks LPA s effects on the neuronal differentiation of human neural stem/progenitor cells, demonstrating its specificity toward LPA signaling. When administered systemically to mice subjected to SCI, B3 substantially reduced glial inflammation and neuronal death. B3-treated animals demonstrated significantly more neuronal survival upstream of the lesion site, with some functional improvement. This study describes the use of anti-LPA monoclonal antibody as a novel therapeutic approach for the treatment of SCI.",
author = "Yona Goldshmit and Rosalia Matteo and Sztal, {Tamar E} and Felix Ellett and Frisca Frisca and Kelli Moreno and Duncan Crombie and Lieschke, {Graham J} and Currie, {Peter D} and Sabbadini, {Roger A} and Alice Pebay",
year = "2012",
doi = "10.1016/j.ajpath.2012.06.007",
language = "English",
volume = "181",
pages = "978 -- 992",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "American Society for Investigative Pathology",
number = "3",

}

Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes. / Goldshmit, Yona; Matteo, Rosalia; Sztal, Tamar E; Ellett, Felix; Frisca, Frisca; Moreno, Kelli; Crombie, Duncan; Lieschke, Graham J; Currie, Peter D; Sabbadini, Roger A; Pebay, Alice.

In: American Journal of Pathology, Vol. 181, No. 3, 2012, p. 978 - 992.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes

AU - Goldshmit, Yona

AU - Matteo, Rosalia

AU - Sztal, Tamar E

AU - Ellett, Felix

AU - Frisca, Frisca

AU - Moreno, Kelli

AU - Crombie, Duncan

AU - Lieschke, Graham J

AU - Currie, Peter D

AU - Sabbadini, Roger A

AU - Pebay, Alice

PY - 2012

Y1 - 2012

N2 - Evidence suggests a proinflammatory role of lysophosphatidic acid (LPA) in various pathologic abnormalities, including in the central nervous system. Herein, we describe LPA as an important mediator of inflammation after spinal cord injury (SCI) in zebrafish and mice. Furthermore, we describe a novel monoclonal blocking antibody raised against LPA that potently inhibits LPA s effect in vitro and in vivo. This antibody, B3, specifically binds LPA, prevents it from interacting with its complement of receptors, and blocks LPA s effects on the neuronal differentiation of human neural stem/progenitor cells, demonstrating its specificity toward LPA signaling. When administered systemically to mice subjected to SCI, B3 substantially reduced glial inflammation and neuronal death. B3-treated animals demonstrated significantly more neuronal survival upstream of the lesion site, with some functional improvement. This study describes the use of anti-LPA monoclonal antibody as a novel therapeutic approach for the treatment of SCI.

AB - Evidence suggests a proinflammatory role of lysophosphatidic acid (LPA) in various pathologic abnormalities, including in the central nervous system. Herein, we describe LPA as an important mediator of inflammation after spinal cord injury (SCI) in zebrafish and mice. Furthermore, we describe a novel monoclonal blocking antibody raised against LPA that potently inhibits LPA s effect in vitro and in vivo. This antibody, B3, specifically binds LPA, prevents it from interacting with its complement of receptors, and blocks LPA s effects on the neuronal differentiation of human neural stem/progenitor cells, demonstrating its specificity toward LPA signaling. When administered systemically to mice subjected to SCI, B3 substantially reduced glial inflammation and neuronal death. B3-treated animals demonstrated significantly more neuronal survival upstream of the lesion site, with some functional improvement. This study describes the use of anti-LPA monoclonal antibody as a novel therapeutic approach for the treatment of SCI.

UR - http://www.sciencedirect.com/science/article/pii/S0002944012004440#

U2 - 10.1016/j.ajpath.2012.06.007

DO - 10.1016/j.ajpath.2012.06.007

M3 - Article

VL - 181

SP - 978

EP - 992

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -